Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 5.18 CHF | 142.07% |
| 2022 | -11.67 CHF | 28.18% |
| 2021 | -16.25 CHF | 68.02% |
| 2020 | -50.81 CHF | -194.38% |
| 2019 | -17.26 CHF | 78.05% |
| 2018 | -78.63 CHF | 4.33% |
| 2017 | -82.19 CHF | -45.47% |
| 2016 | -56.50 CHF | -609.01% |
| 2015 | 11.10 CHF | 169.29% |
| 2014 | -16.02 CHF | -3.22% |
| 2013 | -15.52 CHF | 81.85% |
| 2012 | -85.53 CHF | -12.61% |
| 2011 | -75.95 CHF | -146.91% |
| 2010 | -30.76 CHF | 57.92% |
| 2009 | -73.10 CHF | 48.19% |
| 2008 | -141.10 CHF | -56.97% |
| 2007 | -89.89 CHF | 37.75% |
| 2006 | -144.41 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.67 CHF | 0.0% |
| 2024 Q1 | -0.67 CHF | -109.57% |
| 2023 Q2 | -2.09 CHF | -99.05% |
| 2023 Q3 | 3.50 CHF | 267.46% |
| 2023 Q4 | 7.00 CHF | 100.0% |
| 2023 Q1 | -1.05 CHF | 83.67% |
| 2023 FY | - CHF | 142.07% |
| 2022 Q4 | -6.43 CHF | -102.2% |
| 2022 Q3 | -3.18 CHF | 39.31% |
| 2022 Q2 | -5.24 CHF | -100.0% |
| 2022 Q1 | -2.62 CHF | 62.89% |
| 2022 FY | - CHF | 28.18% |
| 2021 FY | - CHF | 68.02% |
| 2021 Q4 | -7.06 CHF | -85.79% |
| 2021 Q1 | -4.61 CHF | 79.97% |
| 2021 Q2 | -9.22 CHF | -100.0% |
| 2021 Q3 | -3.80 CHF | 58.79% |
| 2020 Q1 | -13.90 CHF | -294.95% |
| 2020 Q2 | -27.80 CHF | -100.0% |
| 2020 Q3 | -11.80 CHF | 57.55% |
| 2020 FY | - CHF | -194.38% |
| 2020 Q4 | -23.01 CHF | -95.0% |
| 2019 Q3 | 3.57 CHF | 114.45% |
| 2019 FY | - CHF | 78.05% |
| 2019 Q2 | -24.70 CHF | -100.0% |
| 2019 Q1 | -12.35 CHF | 28.86% |
| 2019 Q4 | 7.13 CHF | 99.72% |
| 2018 Q4 | -17.36 CHF | -794.85% |
| 2018 FY | - CHF | 4.33% |
| 2018 Q3 | -1.94 CHF | 90.87% |
| 2018 Q2 | -21.25 CHF | 0.0% |
| 2018 Q1 | -21.25 CHF | 26.65% |
| 2017 Q2 | -18.10 CHF | 0.0% |
| 2017 FY | - CHF | -45.47% |
| 2017 Q4 | -28.97 CHF | -1614.2% |
| 2017 Q3 | -1.69 CHF | 90.66% |
| 2017 Q1 | -18.10 CHF | -30.22% |
| 2016 FY | - CHF | -609.01% |
| 2016 Q4 | -13.90 CHF | 0.0% |
| 2016 Q3 | -13.90 CHF | 3.14% |
| 2016 Q2 | -14.35 CHF | 0.0% |
| 2016 Q1 | -14.35 CHF | -239.59% |
| 2015 Q4 | 10.28 CHF | 0.0% |
| 2015 Q2 | -6.40 CHF | 0.0% |
| 2015 FY | - CHF | 169.29% |
| 2015 Q1 | -6.40 CHF | -31.42% |
| 2015 Q3 | 10.28 CHF | 260.62% |
| 2014 Q1 | -3.50 CHF | -3.86% |
| 2014 FY | - CHF | -3.22% |
| 2014 Q4 | -4.87 CHF | 0.0% |
| 2014 Q3 | -4.87 CHF | -39.14% |
| 2014 Q2 | -3.50 CHF | 0.0% |
| 2013 Q2 | -4.40 CHF | 0.0% |
| 2013 Q1 | -4.40 CHF | 87.52% |
| 2013 FY | - CHF | 81.85% |
| 2013 Q4 | -3.37 CHF | 0.0% |
| 2013 Q3 | -3.37 CHF | 23.41% |
| 2012 Q3 | -35.25 CHF | 0.0% |
| 2012 FY | - CHF | -12.61% |
| 2012 Q4 | -35.25 CHF | 0.0% |
| 2011 FY | - CHF | -146.91% |
| 2010 FY | - CHF | 57.92% |
| 2009 FY | - CHF | 48.19% |
| 2008 FY | - CHF | -56.97% |
| 2007 FY | - CHF | 37.75% |
| 2006 FY | - CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Addex Therapeutics Ltd | -0.14 CHF | 3800.0% |
| BB Biotech AG | -3.77 CHF | 237.401% |
| Basilea Pharmaceutica AG | 0.87 CHF | -495.402% |
| Evolva Holding SA | -19.50 CHF | 126.564% |
| Idorsia Ltd | -1.67 CHF | 410.18% |
| Kuros Biosciences AG | -0.38 CHF | 1463.158% |
| Molecular Partners AG | -1.89 CHF | 374.074% |
| Relief Therapeutics Holding AG | -8.35 CHF | 162.036% |